• GPI Home
  • Solutions
    • GPI pulse™
    • GPI Consulting
    • GPI Horizon Methodology
    • Case Studies
  • About Us
    • Our Team
    • Careers
  • Contact Us
  • Discover
    • Blog
    • Events
    • Resources
  • GPI Direct
Month: February 2020
GPI is the sponsor of the drinks reception at PPMA 2020. Join us on the 18th of march!
February 25, 2020 by Global Pricing Innovations (GPI)
GPI will be sponsoring the drinks reception at World Pharma Pricing Market Access & Evidence Congress 2020

Global Pricing Innovations will be sponsoring the drinks reception at World Pharma Pricing Market Access and Evidence Congress 2020 on the 18th March 2020 at Amsterdam’s Beurs van Berlage venue. GPI will be officially launching and providing an exclusive sneak peak at our…

February 20, 2020 by Global Pricing Innovations (GPI)
Capmatinib: The Race to Approval and Optimal Pricing

By Ines Dieringer – Associate Consultant With new mutations which are driving oncogenesis in life-threatening cancers being discovered everyday, the industry looks be keeping pace with targeted therapies for these mutagenic targets. One such example is Novartis’ investigational therapy Capmatinib. This investigational therapy…

Novartis Building
GPI will be attending PPMA 2020. See you there!
February 18, 2020 by Global Pricing Innovations (GPI)
GPI attending World Pharma Pricing, Market Access and Evidence Congress

Global Pricing Innovations will be attending the World Pharma Pricing, Market Access & Evidence Congress in Amsterdam on the 18th and 19th March 2020. Please reach out to our Business Development Manager to arrange a meeting at the event. Musa Kureshy – Business…

February 7, 2020 by Global Pricing Innovations (GPI)
Pfizer’s newest range of biosimilars are set to significantly undercut Roche’s ‘best-selling’ Avastin, Herceptin, and Rituxan on pricing. What will be the impact on Roche’s market share?

Pfizer has planned the launch of its biosimilar competitors in the U.S. to Roche’s cancer drugs, Avastin, Herceptin, and Rituxan, at significantly discounted prices, in comparison to the originators. Experts have noted that the launch of these medicines can lead to substantial savings…

How will Pfizer's discounted biosimilars affect Roche?
Our partners
  • Privacy Policy
  • Terms of Use

| © Copyright 2018 Global Pricing Innovations. All Rights Reserved.

VAT registration: GB225169121